Two new biotech companies – Vitrafy and Renerve – listed today, breaking an eight-month drought of life sciences IPOs on the ASX ... rose 0.8% to 65.5 cents. Paradigm Biopharmaceuticals ...

Speculation of the firm’s potential IPO has circulated following its partnership with Silicon Valley investors Sequoia Capital and Paradigm, which made the first outside investment in Griffin ...